[go: up one dir, main page]

Perl et al., 1987 - Google Patents

Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone

Perl et al., 1987

View PDF
Document ID
17877825470269969347
Author
Perl V
Marquez J
Schally A
Comaru-Schally A
Leal G
Zacharias S
Gomez-Lira C
Publication year
Publication venue
Fertility and sterility

External Links

Snippet

Suppression of the secretion of gonadal steroids by chronic administration of a superactive agonist of luteinizing hormone-releasing hormone (LH-RH) was used for treatment of leiomyomata uteri. Ten menstruating women, presenting with a total of 20 uterine …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids

Similar Documents

Publication Publication Date Title
Perl et al. Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone
Itskovitz et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist
Coddington et al. Long-acting gonadotropin hormone-releasing hormone analogused to treat uteri
Letterie et al. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up
Kettel et al. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist
Heron et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly
Lemay et al. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis
Mathias et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease: Double-blind, placebo-controlled study
Nelson et al. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)
Koyama et al. Effect of postovulatory treatment with a luteinizing hormone-releasing hormone analog on the plasma level of progesterone in women
Vilchez-Martinez et al. Paradoxical effects of D-Trp6-luteinizing hormone-releasing hormone on the hypothalamic-pituitary-gonadal axis in immature female rats
Wallach et al. Clinical uses of luteinizing hormone-releasing hormone
Balasch et al. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot
KLETZKY et al. A sequential pituitary stimulation test in normal subjects and in patients with amenorrhea-galactorrhea with pituitary tumors
Lemay et al. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding
Gohar et al. GnRH in pregnancy
Feuillan et al. Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog
Emons et al. LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview
Golan et al. D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas
ABE et al. Effects of synthetic luteinizing hormone-releasing hormone on plasma levels of luteinizing hormone and follicle-stimulating hormone in man
Klijn et al. LHRH-agonist treatment in metastatic prostate carcinoma
Wallach et al. Clinical applications of luteinizing hormone-releasing hormone
EA009210B1 (en) Use of ln in controlled ovarian huperstimulation
MARSHALL et al. Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (detirelix)
MESSINIS et al. Superovulation induction in women suppresses luteinizing hormone secretion at the pituitary level